Literature DB >> 28869611

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Chad E Mire1,2, Robert W Cross1,2, Joan B Geisbert1,2, Viktoriya Borisevich1,2, Krystle N Agans1,2, Daniel J Deer1,2, Megan L Heinrich3, Megan M Rowland3, Augustine Goba4,5, Mambu Momoh4,5,6, Mathew L Boisen3, Donald S Grant4,5, Mohamed Fullah4,5, Sheik Humarr Khan4,5, Karla A Fenton1,2, James E Robinson7, Luis M Branco3, Robert F Garry3,8,9, Thomas W Geisbert1,2.   

Abstract

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28869611      PMCID： PMC5719877          DOI： 10.1038/nm.4396

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  19 in total

1.  Monitoring of clinical and laboratory data in two cases of imported Lassa fever.

Authors:  Herbert Schmitz; Bernhard Köhler; Thomas Laue; Christian Drosten; Peter J Veldkamp; Stephan Günther; Petra Emmerich; Hans P Geisen; Klaus Fleischer; Matthias F C Beersma; Achim Hoerauf
Journal:  Microbes Infect       Date:  2002-01       Impact factor: 2.700

2.  Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Authors:  Robert W Cross; Chad E Mire; Luis M Branco; Joan B Geisbert; Megan M Rowland; Megan L Heinrich; Augustine Goba; Mambu Momoh; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; James E Robinson; Thomas W Geisbert; Robert F Garry
Journal:  Antiviral Res       Date:  2016-08-13       Impact factor: 5.970

3.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

4.  Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.

Authors:  P B Jahrling; R A Hesse; G A Eddy; K M Johnson; R T Callis; E L Stephen
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

5.  Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.

Authors:  E Leifer; D J Gocke; H Bourne
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

6.  Development of a new vaccine for the prevention of Lassa fever.

Authors:  Thomas W Geisbert; Steven Jones; Elizabeth A Fritz; Amy C Shurtleff; Joan B Geisbert; Ryan Liebscher; Allen Grolla; Ute Ströher; Lisa Fernando; Kathleen M Daddario; Mary C Guttieri; Bianca R Mothé; Tom Larsen; Lisa E Hensley; Peter B Jahrling; Heinz Feldmann
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

7.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

8.  Lassa fever in post-conflict sierra leone.

Authors:  Jeffrey G Shaffer; Donald S Grant; John S Schieffelin; Matt L Boisen; Augustine Goba; Jessica N Hartnett; Danielle C Levy; Rachael E Yenni; Lina M Moses; Mohammed Fullah; Mambo Momoh; Mbalu Fonnie; Richard Fonnie; Lansana Kanneh; Veronica J Koroma; Kandeh Kargbo; Darin Ottomassathien; Ivana J Muncy; Abigail B Jones; Megan M Illick; Peter C Kulakosky; Allyson M Haislip; Christopher M Bishop; Deborah H Elliot; Bethany L Brown; Hu Zhu; Kathryn M Hastie; Kristian G Andersen; Stephen K Gire; Shervin Tabrizi; Ridhi Tariyal; Mathew Stremlau; Alex Matschiner; Darryl B Sampey; Jennifer S Spence; Robert W Cross; Joan B Geisbert; Onikepe A Folarin; Christian T Happi; Kelly R Pitts; F Jon Geske; Thomas W Geisbert; Erica Ollmann Saphire; James E Robinson; Russell B Wilson; Pardis C Sabeti; Lee A Henderson; S Humarr Khan; Daniel G Bausch; Luis M Branco; Robert F Garry
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20

9.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

10.  Imported Lassa fever, Pennsylvania, USA, 2010.

Authors:  Valerianna Amorosa; Adam MacNeil; Ryan McConnell; Ami Patel; Katherine E Dillon; Keith Hamilton; Bobbie Rae Erickson; Shelley Campbell; Barbara Knust; Deborah Cannon; David Miller; Craig Manning; Pierre E Rollin; Stuart T Nichol
Journal:  Emerg Infect Dis       Date:  2010-10       Impact factor: 6.883
View more
  42 in total

1.  Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.

Authors:  Markus H Kainulainen; Jessica R Spengler; Stephen R Welch; JoAnn D Coleman-McCray; Jessica R Harmon; Florine E M Scholte; Cynthia S Goldsmith; Stuart T Nichol; César G Albariño; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

2.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

3.  Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.

Authors:  Robert W Cross; Rong Xu; Demetrius Matassov; Stefan Hamm; Theresa E Latham; Cheryl S Gerardi; Rebecca M Nowak; Joan B Geisbert; Ayuko Ota-Setlik; Krystle N Agans; Amara Luckay; Susan E Witko; Lena Soukieh; Daniel J Deer; Chad E Mire; Heinz Feldmann; Christian Happi; Karla A Fenton; John H Eldridge; Thomas W Geisbert
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

4.  Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.

Authors:  Peter Okokhere; Andres Colubri; Chukwuemeka Azubike; Christopher Iruolagbe; Omoregie Osazuwa; Shervin Tabrizi; Elizabeth Chin; Sara Asad; Ehi Ediale; Mojeed Rafiu; Donatus Adomeh; Ikponmwosa Odia; Rebecca Atafo; Chris Aire; Sylvanus Okogbenin; Meike Pahlman; Beate Becker-Ziaja; Danny Asogun; Terrence Fradet; Ben Fry; Stephen F Schaffner; Christian Happi; George Akpede; Stephan Günther; Pardis C Sabeti
Journal:  Lancet Infect Dis       Date:  2018-03-06       Impact factor: 25.071

Review 5.  Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.

Authors:  Lutz Gieselmann; Christoph Kreer; Meryem Seda Ercanoglu; Nathalie Lehnen; Matthias Zehner; Philipp Schommers; Julian Potthoff; Henning Gruell; Florian Klein
Journal:  Nat Protoc       Date:  2021-05-25       Impact factor: 13.491

6.  Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Authors:  Kathryn M Hastie; Robert W Cross; Stephanie S Harkins; Michelle A Zandonatti; Anatoliy P Koval; Megan L Heinrich; Megan M Rowland; James E Robinson; Thomas W Geisbert; Robert F Garry; Luis M Branco; Erica Ollmann Saphire
Journal:  Cell       Date:  2019-08-08       Impact factor: 66.850

Review 7.  Lymphocytic Choriomeningitis-Emerging Trends of a Neglected Virus: A Narrative Review.

Authors:  Tatjana Vilibic-Cavlek; Vladimir Savic; Thomas Ferenc; Anna Mrzljak; Ljubo Barbic; Maja Bogdanic; Vladimir Stevanovic; Irena Tabain; Ivana Ferencak; Snjezana Zidovec-Lepej
Journal:  Trop Med Infect Dis       Date:  2021-05-25

8.  Lassa hemorrhagic shock syndrome-on-a-chip.

Authors:  Huaqi Tang; Yasmine Abouleila; Alireza Mashaghi
Journal:  Biotechnol Bioeng       Date:  2020-12-04       Impact factor: 4.530

9.  Time to reconsider the role of ribavirin in Lassa fever.

Authors:  Alex Paddy Salam; Vincent Cheng; Tansy Edwards; Piero Olliaro; Jonathan Sterne; Peter Horby
Journal:  PLoS Negl Trop Dis       Date:  2021-07-08

10.  Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.

Authors:  J Maximilian Fels; Daniel P Maurer; Andrew S Herbert; Ariel S Wirchnianski; Olivia Vergnolle; Robert W Cross; Dafna M Abelson; Crystal L Moyer; Akaash K Mishra; Jennifer T Aguilan; Ana I Kuehne; Noel T Pauli; Russell R Bakken; Elisabeth K Nyakatura; Jan Hellert; Gregory Quevedo; Leslie Lobel; Stephen Balinandi; Julius J Lutwama; Larry Zeitlin; Thomas W Geisbert; Felix A Rey; Simone Sidoli; Jason S McLellan; Jonathan R Lai; Zachary A Bornholdt; John M Dye; Laura M Walker; Kartik Chandran
Journal:  Cell       Date:  2021-06-01       Impact factor: 66.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.